603087 Stock Overview
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Gan & Lee Pharmaceuticals. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥48.00 |
| 52 Week High | CN¥62.90 |
| 52 Week Low | CN¥32.10 |
| Beta | 1.61 |
| 1 Month Change | 19.31% |
| 3 Month Change | 18.55% |
| 1 Year Change | 34.60% |
| 3 Year Change | -64.67% |
| 5 Year Change | n/a |
| Change since IPO | -26.30% |
Recent News & Updates
Shareholder Returns
| 603087 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 11.3% | -1.6% | -0.4% |
| 1Y | 34.6% | -24.8% | -14.4% |
Return vs Industry: 603087 exceeded the CN Biotechs industry which returned -24.8% over the past year.
Return vs Market: 603087 exceeded the CN Market which returned -14.4% over the past year.
Price Volatility
| 603087 volatility | |
|---|---|
| 603087 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603087's share price has been volatile over the past 3 months.
Volatility Over Time: 603087's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,057 | Kai Du | www.ganlee.com |
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices.
Gan & Lee Pharmaceuticals. Fundamentals Summary
| 603087 fundamental statistics | |
|---|---|
| Market cap | CN¥28.32b |
| Earnings (TTM) | CN¥386.85m |
| Revenue (TTM) | CN¥2.61b |
73.2x
P/E Ratio10.8x
P/S RatioIs 603087 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603087 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.61b |
| Cost of Revenue | CN¥698.84m |
| Gross Profit | CN¥1.91b |
| Other Expenses | CN¥1.52b |
| Earnings | CN¥386.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 73.23% |
| Net Profit Margin | 14.82% |
| Debt/Equity Ratio | 0.02% |
How did 603087 perform over the long term?
See historical performance and comparison